Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22552219 | 1.00 | DHODH (1.00) | DHODH | |
| SCHEMBL29404093 | 1.00 | DHODH (1.00) | DHODH | |
| SCHEMBL29401428 | 1.00 | DHODH (1.00) | DHODH | |
| SCHEMBL22552202 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL22552173 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL29401620 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL29401439 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL22552475 | 0.81 | DHODH (0.78) | DHODH | |
| SCHEMBL22552494 | 0.81 | DHODH (0.78) | DHODH | |
| SCHEMBL22552338 | 0.81 | DHODH (0.78) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | claimed |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2022-11-22 | — | — | US | claimed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2020-10-22 | — | — | US | claimed |
| WO-2020212897-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-10-22 | — | — | WO | claimed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| US-20240261292-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2024-08-08 | — | — | US | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2022-11-22 | — | — | US | disclosed |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2022-09-22 | — | — | US | disclosed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2020-10-22 | — | — | US | disclosed |
| WO-2020212897-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212897-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | DHODH 1/4885 |
| US-20240261292-A1 | COMBINATION THERAPIES | IDH3B, DHODH, IDH3A | DHODH 2/4885 |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | DHODH 1/4885 |
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | DHODH 3385/4885 |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | DHODH 1/4885 |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | DHODH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.